AstraZeneca Pharma India Certificate on Depositories and Participants Regulations

AstraZeneca Pharma India has received a certificate confirming compliance with Regulation 74(5) of the SEBI (Depositories and Participants) Regulations, 2018, for the period October 1, 2025, to October 31, 2025. The certificate, issued by Integrated Registry Management Services, ensures adherence to dematerialization processes and security standards.

Compliance Certificate Received

AstraZeneca Pharma India has received a certificate from Integrated Registry Management Services Private Limited confirming compliance with Regulation 74(5) of the SEBI (Depositories and Participants) Regulations, 2018. The certificate is dated November 6, 2025 and covers the period from October 1, 2025 to October 31, 2025.

Details of Compliance

The certificate confirms adherence to regulations related to the dematerialization of securities. This includes ensuring that dematerialized securities are listed on relevant stock exchanges, that certificates of security are properly handled, and that the depository is correctly recorded as the registered owner. Integrated Registry Management Services, the Registrar and Transfer Agent (RTA), issued the certificate, confirming compliance with the stated regulations for AstraZeneca Pharma India.

Source: BSE

Previous Article

HEG Limited Board Approves Unaudited Financial Results and Subsidiary Investment

Next Article

CESC Limited Certificate under Regulation 74(5) for October 2025

Write a Comment

Leave a Comment

Your email address will not be published. Required fields are marked *